Center of cancer systems biology second annual workshop-tumor metronomics: Timing and dose level dynamics

Cancer Research

Volumn 73, Issue 10, 2013, Pages 2949-2954

  Hahnfeldt, Philip ^a   Hlatky, Lynn ^a   Klement, Giannoula Lakka ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; MAFOSFAMIDE; VINBLASTINE;

BRAIN CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RESEARCH; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CONFERENCE PAPER; HUMAN; MATHEMATICAL MODEL; MAXIMUM TOLERATED DOSE; METRONOMIC CHEMOTHERAPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SURVIVAL RATE; SYSTEMS BIOLOGY;

ANTINEOPLASTIC AGENTS; HUMANS; MAXIMUM TOLERATED DOSE; NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SYSTEMS BIOLOGY; TIME FACTORS;

EID: 84877850988     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3807     Document Type: Conference Paper

References (45)

1. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7. (Pubitemid 30217688)
2. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24. (Pubitemid 30217701)
3. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60: 1878-86. (Pubitemid 30207647)
4. Kamen BA, Rubin E, Aisner J, Glatstein E. High-time chemotherapy or high time for low dose. J Clin Oncol 2000;18:2935-7. (Pubitemid 30644116)
5. Skipper HE, Schabel FM Jr, Bell M, Thomson JR, Johnson S. On the curability of experimental neoplasms. I. Amethopterin and mouse leukemias. Cancer Res 1957;17:717-26.
6. Skipper HE, Schabel FM Jr, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 1970;54:431-50.
7. DeNardo DG, Johansson M, Coussens LM. Inflaming gastrointestinal oncogenic programming. Cancer Cell 2008;14:7-9. (Pubitemid 351885501)
8. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007; 9:212.
9. Frost P, Kamen BA. The bullseye of cancer therapy: A moving target. Curr Opin Pharmacol 2003;3:335-7. (Pubitemid 36908935)
10. Weitman SD, Glatstein E, Kamen BA. Back to the basics: The importance of concentration x time in oncology. J Clin Oncol 1993;11:820-1. (Pubitemid 23146073)
11. Lauer SJ, Shuster JJ, Mahoney DH Jr, Winick N, Toledano S, Munoz L, et al. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group phase III randomized trial. Leukemia. 2001;15: 1038-45. (Pubitemid 32717272)
12. Hahnfeldt P, Folkman J, Hlatky L. Minimizing long-term tumor burden: The logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol. 2003;220:545-54. (Pubitemid 36293163)
13. Ledzewicz U, Schättler H. Optimal bang-bang controls for a twocompartment model in cancer chemotherapy. J Optim Theory Appl. 2002;114:609-37. (Pubitemid 39583314)
14. Ledzewicz U, Schättler H. Drug resistance in cancer chemotherapy as an optimal control problem. Discrete Contin Dyn Syst Ser B 2006;6: 129-50. (Pubitemid 43294241)
15. Pasquier E, Andre N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: Implications for cancer treatment. Curr Cancer Drug Targets 2007;7:566-81. (Pubitemid 47358143)
16. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: New rationale for new directions. Nat Rev Clin Oncol 2010;7:455-65.
17. Pasquier E, Andre N. New therapeutic advances and perspectives in tumour angiogenesis. Curr Cancer Drug Targets 2010;10:877-8.
18. Pasquier E, Tuset MP, Street J, Sinnappan S, Mackenzie KL, Braguer D, et al. Concentration-and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells. Angiogenesis 2013;16:373-86.
19. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002;8: 221-32. (Pubitemid 34101482)
20. Panetta JC, Gajjar A, Hijiya N, Hak LJ, Cheng C, Liu W, et al. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther 2009;86:651-8.
21. Panetta JC, Sparreboom A, Pui CH, Relling MV, Evans WE. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput Biol 2010;6:e1001019.
22. Hubbard KE, Schaiquevich P, Bai F, Fraga CH, Miller L, Panetta JC, et al. Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood. Biomed Chromatogr 2009;23:707-13.
23. Benzekry S, Andre N, Benabdallah A, Ciccolini J, Faivre C, Hubert F, et al. Modeling the impact of anticancer agents on metastatic spreading. Math Model Nat Phenom 2012;7:306-6.
24. Peyrl A, Chocholous M, Kieran MW, Azizi AA, Prucker C, Czech T, et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer 2012;59:511-7.
25. Ferrari A, Grosso F, Stacchiotti S, Meazza C, Zaffignani E, Marchiano A, et al. Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor. Pediatr Blood Cancer 2007;49:864-6. (Pubitemid 47519531)
26. Andre N, Abed S, Orbach D, Alla CA, Padovani L, Pasquier E, et al. Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget 2011;2: 960-5.
27. Kebudi R, Gorgun O, Ayan I. Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatr Blood Cancer 2004;42:320-4. (Pubitemid 38327624)
28. Inoue S, Onwuzurike N. Venorelbine and methotrexate for the treatment of Rosai-Dorfman disease. Pediatr Blood Cancer 2005;45:84-5; author reply 86.
29. Kuttesch JFJr, Krailo MD, Madden T, Johansen M, Bleyer A. Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: A Children's Oncology Group study. Pediatr Blood Cancer 2009;53:590-3.
30. Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy: From the research laboratory into the oncology clinic. Ann Oncol 2002;13:12-5. (Pubitemid 34436715)
31. Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20:79-86. (Pubitemid 34074682)
32. Ma J, Waxman DJ. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther 2008;7:79-89.
33. Doloff JC, Waxman DJ. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res 2012;72:1103-15.
34. Jia L, Waxman DJ. Thrombospondin-1 and pigment epitheliumderived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis. Cancer Lett. 2013;330:241-9.
35. Folkman J, Hahnfeldt P, Hlatky L. Cancer: Looking outside the genome. Nat Rev Mol Cell Biol. 2000;1:76-9.
36. Felgenhauer JL, Nieder ML, Krailo MD, Bernstein ML, Henry DW, Malkin D, et al. A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893. Pediatr Blood Cancer 2013;60:409-14.
37. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977;61:1307-17. (Pubitemid 8204100)
38. Norton L, Simon R. Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst 1977;58:1735-41. (Pubitemid 8118751)
39. Sugarman S, Wasserheit C, Hodgman E, Coglianese M, D'Alassandro A, Fornier M, et al. A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma. Breast Cancer Res Treat 2009;115:609-12.
40. Fornier M, Norton L. Dose-dense adjuvant chemotherapy for primary breast cancer. Breast Cancer Res 2005;7:64-9. (Pubitemid 40352672)
41. Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, et al. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dosedense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res 2001;7:3934-41. (Pubitemid 34044611)
42. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9. (Pubitemid 46594092)
43. Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XH, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell 2009;139: 1315-26.
44. Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E, et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 2006;16:1465-79. (Pubitemid 44878486)
45. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, Kendall J, et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010;20:68-80.